MEDICATION ADHERENCE COMPARING TOBRAMYCIN INHALATION POWDER AND SOLUTION IN PATIENTS WITH CYSTIC FIBROSIS USING THE DUTCH PHARMO DATABASE NETWORK

被引：0
|
作者：
Overbeek, J. [2 ]
Kuiper, J. [2 ]
Evers, K. [3 ]
Putzeist, M. [3 ]
Mastoridis, P. [1 ]
Ong, S. H. [4 ]
Herk-Sukel, M. [2 ]
机构：
[1] Novartis Pharmaceut, E Hanover, NJ USA
[2] PHARMO Inst, Utrecht, Netherlands
[3] Novartis Pharma BV, Arnhem, Netherlands
[4] Novartis Pharma AG, Basel, Switzerland
来源：
PEDIATRIC PULMONOLOGY | 2015年 / 50卷
关键词：
D O I：
暂无
中图分类号：
R72 [儿科学];
学科分类号：
100202 ;
摘要：
460
引用
收藏
页码：365 / 365
页数：1
相关论文
共 50 条
  • [31] Tobramycin Inhalation Powder: A Review of Its Use in the Treatment of Chronic Pseudomonas aeruginosa Infection in Patients with Cystic Fibrosis
    McKeage, Kate
    DRUGS, 2013, 73 (16) : 1815 - 1827
  • [32] Long-term safety of tobramycin inhalation powder in patients with cystic fibrosis: phase IV (ETOILES) study
    Sommerwerck, Urte
    Virella-Lowell, Isabel
    Angyalosi, Gerhild
    Viegas, Andrea
    Cao, Weihua
    Debonnett, Laurie
    CURRENT MEDICAL RESEARCH AND OPINION, 2016, 32 (11) : 1789 - 1795
  • [33] IN VITRO AEROSOL DELIVERY PERFORMANCE OF TOBRAMYCIN POWDER FOR INHALATION (TOBI® PODHALER™) USING INSPIRATORY FLOW PROFILES FROM CYSTIC FIBROSIS PATIENTS
    Haynes, A.
    Ament, B.
    Heng, C.
    Le, J.
    Ung, K.
    Rao, R.
    Malcolmson, R.
    Weers, J.
    Pavkov, R.
    Heuerding, S.
    Geller, D.
    PEDIATRIC PULMONOLOGY, 2013, 48 : 352 - 352
  • [34] Inhaled medication and inhalation devices for lung disease in patients with cystic fibrosis poor adherence and the need to address it
    Duff, Alistair J. A.
    Latchford, Gary J.
    JOURNAL OF CYSTIC FIBROSIS, 2010, 9 (06) : 455 - 456
  • [35] Budget Impact Model of Adding Tobramycin Inhalation Solution for Treatment of Pseudomonas aeruginosa in Cystic Fibrosis Patients.
    Woodward, T. C.
    Sacco, P.
    Brown, R.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2009, 179
  • [36] COST IMPACT OF INITIATION OF TOBRAMYCIN SOLUTION FOR INHALATION (TSI) IN PATIENTS WITH CYSTIC FIBROSIS (CF) IN A MANAGED CARE POPULATION
    Kuhn, R. J.
    Wertz, D. A.
    Zhang, J.
    Chang, C.
    Stephenson, J. J.
    PEDIATRIC PULMONOLOGY, 2010, : 367 - 368
  • [37] Effects of tobramycin solution for inhalation on global ratings of quality of life in patients with cystic fibrosis and Pseudomonas aeruginosa infection
    Quittner, AL
    Buu, A
    PEDIATRIC PULMONOLOGY, 2002, 33 (04) : 269 - 276
  • [38] Tobramycin Inhalation Powder Is Effective and Safe in the Treatment of Chronic Pulmonary Pseudomonas aeruginosa (Pa) Infection in Patients with Cystic Fibrosis
    Konstan, M. W.
    Geller, D. E.
    Brockhaus, F.
    Zhang, J.
    Angyalosi, G.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2009, 179
  • [39] Treatment compliance in cystic fibrosis patients with chronic Pseudomonas aeruginosa infection treated with tobramycin inhalation powder: The FREE study
    Blasi, Francesco
    Carnovale, Vincenzo
    Cimino, Giuseppe
    Lucidi, Vincenzina
    Salvatore, Donatello
    Messore, Barbara
    Bartezaghi, Marta
    Muscianisi, Elisa
    Porpiglia, Pasquale Alberto
    RESPIRATORY MEDICINE, 2018, 138 : 88 - 94
  • [40] Tobramycin inhalation powder for the treatment of pulmonary Pseudomonas aeruginosa infection in patients with cystic fibrosis: a review based on clinical evidence
    Hamed, Kamal
    Debonnett, Laurie
    THERAPEUTIC ADVANCES IN RESPIRATORY DISEASE, 2017, 11 (05) : 193 - 209
12345